Michael Liebowitz, MD: The Mental Health Impact of COVID-19
For many patients suffering from depression or anxiety, the added stress of the pandemic has led to a medication change.
For many patients suffering from depression or anxiety, the added stress of the pandemic has led to a medication change.
In an interview, Ryan McLaughlin discussed the ethical concerns regarding treating psychiatric illness with cannabis.
Both overall TEAEs and serious TEAEs were numerically higher in those receiving upadacitinib compared with adalimumab.
In this interview, Browning discusses his team’s trial data and the implications of the FDA’s decision to accept the supplemental new drug application for tapinarof…
Findings indicated treatment with colchicine resulted in a significant reduction in mortality rate compared with placebo or standard care.
Devanand reviews lecanemab and the advent of blood biomarkers for dementia and Alzheimer’s management at APA 2024.
Marmar explains what anticipated blood and molecular profiling of PTSD may provide psychiatrists treating patients.
HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care…
Kane explains why newer long-acting injectables and clozapine may be under-utilized still in the management of schizophrenia.
In an interview with Andrew Chen, MD, he explained why patients might need to turn to more adverse event prone anxiety medications.
New literature review data suggests doxazosin is related to less incident hypotension than prazosin, while providing clinical benefit, in PTSD patients with condition-related nightmares.